BrightGene Bio-Medical Technology Co Debt
The Debt of BrightGene Bio-Medical Technology Co (688166.SS) as of Oct 24, 2026 is 1.39 B CNY. In the previous year, Debt was 1.57 B CNY — a change of -11.30% (lower).
Get this data via API
Financial Data API
Debt
1.39 BCNY
YoY
-11.30%
Last updated:
In 2025, BrightGene Bio-Medical Technology Co's total debt was 1.39 B CNY, a -11.30% change from the 1.57 B CNY total debt recorded in the previous year.
The BrightGene Bio-Medical Technology Co Debt history
3 Years
10 Years
25 Years
Max
| YEAR | Debt | YoY |
|---|---|---|
| 1.39 BCNY | -11.30% | |
| 1.57 BCNY | -3.07% | |
| 1.61 BCNY | +2.47% | |
| 1.58 BCNY | +154.74% | |
| 618.69 MCNY | +698.15% | |
| 77.52 MCNY | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BrightGene Bio-Medical Technology Co Stock analysis
Debt Details
Understanding BrightGene Bio-Medical Technology Co's Debt Structure
BrightGene Bio-Medical Technology Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing BrightGene Bio-Medical Technology Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to BrightGene Bio-Medical Technology Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in BrightGene Bio-Medical Technology Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock
Debt of BrightGene Bio-Medical Technology Co is 1.39 B CNY in 2025.
Debt of BrightGene Bio-Medical Technology Co changed from 1.57 B CNY to 1.39 B CNY, representing a -11.30% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Debt BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.
Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's BrightGene Bio-Medical Technology Co historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — BrightGene Bio-Medical Technology Co
All Key Metrics — BrightGene Bio-Medical Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth